NewAmsterdam Pharma Director Resigns as Company Reports 2026 Annual Meeting Results

NewAmsterdam Pharma Co N.V. reported the departure of a director and the approval of multiple proposals at its 2026 annual general meeting of shareholders, according to an 8-K filed with the SEC on June 3, 2026.

The filing discloses one Item 5.02 event concerning the resignation of a director, though the named individual, exact role, effective date and any cited cause are not detailed beyond the standard disclosure requirement. Item 5.07 covers the submission of matters to a vote of security holders at the annual meeting. Item 9.01 references exhibits filed with the report.

The company, which maintains its corporate headquarters in the Netherlands and trades on a U.S. exchange, must now operate with an adjusted board. Director departures require the company to assess whether the board still meets Nasdaq or other exchange independence and committee-composition rules; any resulting vacancies must typically be filled within the timelines set by the company’s articles of association and Dutch corporate law.

Downstream, the filing starts the 4-business-day clock under SEC rules for any further amendments or disclosures if additional details on the resignation emerge. The company will also need to update its proxy-statement disclosures for the next annual meeting to reflect the new board composition.

If the departing director held a committee seat, the audit, compensation or nominating committees must reconstitute to maintain compliance with exchange listing standards and the company’s internal governance documents. These operational steps follow automatically from the 8-K filing and the vote results now on the public record.

This marks the latest board-level change for NewAmsterdam Pharma since it became a public company. The June 3 filing is the official SEC record; no separate Form 8-K for the full voting results was referenced beyond the combined disclosure.

The company’s next required filings will incorporate the updated board information into its Form 20-F annual report or any subsequent proxy materials submitted to the SEC.